ArticleCancers2025

Radiological, Pathological, and Surgical Outcomes with Neoadjuvant Cemiplimab for Stage II-IV Cutaneous Squamous Cell Carcinoma in the Deep Sequencing in Cutaneous Squamous Cell Carcinomas (DISCERN) Trial.

Annette M Lim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.